Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee.
OBJECTIVE
Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.


METHODS
From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.


RESULTS
Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.


CONCLUSIONS
CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.
Division of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Kyung A
KA
Kwon
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Sung Yong
SY
Oh
Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Korea.
Ho Young
HY
Kim
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Hyo Song
HS
Kim
Division of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Ha Young
HY
Lee
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Tae Min
TM
Kim
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ho Yeong
HY
Lim
Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
Na-Ri
NR
Lee
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Hyo Jin
HJ
Lee
Division of Medical Oncology, Department of Internal Medicine, The Catholic University College of Medicine, Seoul, Korea.
Sook Hee
SH
Hong
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Sun Young
SY
Rha
Kidney; Prognosis; Renal cell carcinoma; Treatment